Historical record - last NADAC publication: 1/22/2014
Product Information
EPIVIR 300 MG TABLET is a brand product labeled by ViiV Healthcare Company, priced at $13.2940 per EA under NDC 49702020413. Its NADAC has been published 61 times since Dec 18, 2013.
The High Outlier badge above means this manufacturer's average price in the lamivudine market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
300 mg/1
Manufacturer
ViiV Healthcare CompanyNDC
49702020413
Classification
Brand
Dosage Form
TABLET, FILM COATED
Route
ORAL
Last Updated
1/22/2014
Active Ingredients
LAMIVUDINEApproval Type
New Drug (NDA)
FDA Application
NDA020564On Market Since
10/4/2010
Pharmacological Classes
Price Statistics
The NADAC for EPIVIR 300 MG TABLET has been published 61 times since Dec 18, 2013, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $13.2940 per EA |
|---|---|
| All-time high | $13.3383 (Jan 15, 2014) |
| All-time low | $13.2940 (Jan 22, 2014) |
| Median price | $13.2940 |
| Average price | $13.2976 |
| Largest weekly change | -0.3% (Jan 22, 2014) |
| Weeks tracked | 61 |
| Tracking since | Dec 18, 2013 |
Generic Alternatives
The matcher finds 1 NADAC-published product sharing this drug's active ingredient, strength, and dosage form across 1 manufacturer (up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 90% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Frequently asked questions
What is the NADAC price of EPIVIR 300 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for EPIVIR 300 MG TABLET, manufactured by ViiV Healthcare Company, is $13.2940 per EA (NDC 49702020413), effective Feb 11, 2015.
How has the price of EPIVIR 300 MG TABLET changed over time?
Over the history we have for it, the NADAC for EPIVIR 300 MG TABLET has held within roughly two percent of its current level. It has been tracked across 61 weekly CMS publications since Dec 18, 2013.
What are the highest and lowest recorded NADAC prices for EPIVIR 300 MG TABLET?
Since Dec 18, 2013, the NADAC for EPIVIR 300 MG TABLET has ranged from a low of $13.2940 (Jan 22, 2014) to a high of $13.3383 (Jan 15, 2014), with a median of $13.2940 per EA.
Are there cheaper alternatives to EPIVIR 300 MG TABLET?
Yes. 1 NADAC-published product shares the same active ingredient, strength, and dosage form. The lowest-priced option, LAMIVUDINE 300 MG TABLET, is $1.3483 per EA — about 90% below EPIVIR 300 MG TABLET.
Who manufactures EPIVIR 300 MG TABLET?
EPIVIR 300 MG TABLET (NDC 49702020413) is labeled by ViiV Healthcare Company, and CMS classifies it as a brand product.
Related Drugs
Same classification